CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Diabetic peripheral neuropathic painNeuralgia

Inactive Indication

FibromyalgiaNeuralgia, Postherpetic

Originator Organization

Daiichi Sankyo Co., Ltd.

Active Organization

Daiichi Sankyo Co., Ltd.Jilin Tianheng Pharmaceutical Co., Ltd.

Daiichi Sankyo, Inc.

Inactive Organization-

License Organization

Daiichi Sankyo Co., Ltd.

A. Menarini Asia-Pacific Holdings Pte Ltd.

Drug Highest PhaseApproved

First Approval Date

Japan (08 Jan 2019),

Neuralgia

Regulation-

Structure/Sequence

Molecular FormulaC18H25NO5S

InChIKeyOKJXJRVWXYRSAN-TXULWXBWSA-N

CAS Registry1138245-21-2

138

Clinical Trials associated with Mirogabalin Besilate

CTR20262671

/ Active, not recruitingNot Applicable

苯磺酸美洛加巴林片人体生物等效性研究

[Translation] Human bioequivalence study of melogabalin besylate tablets

本试验旨在研究健康试验参与者单次空腹和餐后口服浙江诺得药业有限公司研制、生产的苯磺酸美洛加巴林片（5 mg）的药代动力学特征；以第一三共株式会社持证、生产的苯磺酸美洛加巴林片（Tarlige®，5 mg）为参比制剂，比较两制剂中药动学参数Cmax和AUC0-t，评价两制剂的人体生物等效性，并观察两制剂在健康试验参与者中的安全性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of melogabalin besylate tablets (5 mg) developed and manufactured by Zhejiang Nuode Pharmaceutical Co., Ltd., administered orally once on an empty stomach and after a meal in healthy participants. Merogabalin besylate tablets (Tarlige®, 5 mg) manufactured by Daiichi Sankyo Co., Ltd. were used as a reference formulation. The pharmacokinetic parameters Cmax and AUC0-t of the two formulations were compared to evaluate their bioequivalence in humans and to observe their safety in healthy participants.

Start Date21 Sep 2026

Sponsor / Collaborator

Zhejiang NuoDe Pharmaceutical Co., Ltd.

NCT07803393

/ Not yet recruitingPhase 1IIT

Mirogabalin Combined With Educational-Behavioral Modification Program Versus Educational-Behavioral Modification Program Alone for Interstitial Cystitis/Bladder Pain Syndrome: a Multicenter Randomized Controlled Trial

The goal of this clinical trial is to learn whether adding mirogabalin to educational-behavioral modification program (EBMP) improves symptoms and safety outcomes for adults living with interstitial cystitis/bladder pain syndrome (IC/BPS).
The main questions this study aims to answer are:
1. Does combined mirogabalin and EBMP treatment produce better overall symptom improvement after 12 weeks compared with EBMP alone?
2. Is combination treatment safe and well-tolerated in adults with IC/BPS?
Researchers will compare two treatment groups to test these questions. Eligible adult participants will be randomly assigned in a 1-to-1 ratio to one of two groups. Randomization is performed through a certified online clinical trial platform with allocation concealment.
Participants will:
* Receive either standard EBMP alone or EBMP plus oral mirogabalin for 12 weeks
* Follow a flexible mirogabalin dosing schedule in the combination group, starting at a low dose and gradually increasing based on individual tolerance
* Complete regular clinic visits, bladder diaries, and symptom questionnaires at baseline, week 2, week 6, and week 12
* Undergo repeated assessments of pain, bladder function, quality of life, sleep status, and mood during treatment
This is an open-label study, meaning participants and treating clinicians know the assigned treatment. To avoid assessment bias, outcome evaluators remain blinded to group allocation throughout the trial.
The primary study outcome is participants' overall symptom response after 12 weeks of treatment. Secondary outcomes include changes in bladder pain, urinary frequency, functional bladder capacity, IC/BPS-specific symptoms, quality of life, sleep quality, and depressive symptoms. The study also monitors all adverse events to evaluate treatment safety over 12 weeks.

Start Date20 Sep 2026

Sponsor / Collaborator

Beijing Tiantan Hospital

CTRI/2026/08/115786

/ Not yet recruitingPhase 3

A Randomized, Multi-Centric, Double-blind, Double Dummy, Active Controlled, Parallel-group, Comparative Study to Evaluate Efficacy and Safety of Mirogabalin Compared to Pregabalin in Patients with Neuropathic Pain. - NIL

Start Date24 Aug 2026

Sponsor / Collaborator

Torrent Pharmaceuticals Ltd.

100 Clinical Results associated with Mirogabalin Besilate

100 Translational Medicine associated with Mirogabalin Besilate

100 Patents (Medical) associated with Mirogabalin Besilate

174

Literatures (Medical) associated with Mirogabalin Besilate

01 Dec 2026·CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Association Between the Use of Gabapentinoids and Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis

Review

Author: Sridevi, Bhima ; Chittelu, Blessy ; Pelluri, Ranakishor ; Thommandru, Sravani ; Muteti, Paul Kitonga ; Royyuru, Lalasa Sri Tulasi ; Mateti, Uday Venkat ; Varukolu, Suresh ; Rachamanti, Ramya ; Gurram, Prasada Chowdari ; Nalluri, Buchi Naidu ; Gopal, Kannan ; Nalukenge, Birungi Mariam ; Nagasubramanian, Vanitha Rani ; Patnam, Nageswari ; L, Ananthesh

Background:

Evidence on gabapentinoids and its respiratory safety among the patients with chronic obstructive pulmonary disease(COPD) or asthma are remains uncertain.

Objective:

To evaluate the risk of exacerbations with gabapentinoids.

Methods:

A thorough literature search up to January 2026 was done across different databases to find real-world studies examining gabapentinoid exposure and respiratory outcomes. The pooled hazard ratios (HRs), 95% confidence interval (CI) and incidence rate ratios (IRRs) were calculate using random-effects models. Subgroup and sensitivity analysis were also performed for included studies. Quality of studies was evaluated using the Newcastle-Ottawa Scale.

Results:

Four cohort studies (seven reports) included to this analysis. Gabapentinoids use did not associated with exacerbations of COPD or asthma (HR = 1.12, 95% CI: 0.93-1.34; p = 0.23; I² = 90.7%). Further, analysis was stratified by gabapentinoid class and clinical indications. Subgroup analyses showed increased exacerbation risk with gabapentin (HR = 1.27, 95% CI: 1.02-1.58) and pregabalin (HR=1.37, 95% CI: 1.12-1.67), whereas mirogabalin showed no significant association. Elevated risk was consistent across clinical indications (HR = 1.42, 95% CI: 1.35-1.48). Incidence rate analysis demonstrated higher exacerbation incidence among gabapentinoid users (IRR = 1.41, 95% CI: 1.10-1.81; p=0.006).

Conclusions:

Overall, there was no significant association with gabapentinoids. However, gabapentin and pregabalin were linked to increased risk of exacerbations. Therefore, future long-term studies are required to establish this association with underlying biological mechanisms. [PROSPERO ID: CRD420251248968].

01 Nov 2026·DIABETES OBESITY & METABOLISM

First‐In‐Human Study of Mirogabalin ( BM2216 ) Sustained‐Release Tablets: Safety, Tolerability, Pharmacokinetics, Food Effect and Dose Proportionality With Comparison to Mirogabalin Besylate in Healthy Participants

Article

Author: Song, Peiyang ; Chen, Yuan ; Wan, Lei ; Tang, Chengyong ; Zhao, Hongtao ; Li, Zhongping ; Zhu, Mingxue

ABSTRACT:

Aim:

To characterise the pharmacokinetics (PKs) and safety of BM2216 sustained‐release (SR) tablets after single‐dose oral administration under fasted/fed conditions in healthy participants, assess the effect of food and dose proportionality, and compare the single and multiple‐dose PK of BM2216 SR tablets with mirogabalin besylate tablets to estimate the bioavailability.

Materials and Methods:

This was a single‐centre, randomised, open‐label, phase I study conducted in healthy adult participants aged 18–45 years old, consisting of three parts: Part 1 (Food effect and single‐dose PK comparison): 18 participants were 1:1:1 randomised into three sequences: (1) 16.5 mg BM2216 (fasting 18:00, QD); (2) 15 mg mirogabalin besylate tablets (fasting 18:00/next‐day 6:00, 7.5 mg/dose); (3) 16.5 mg BM2216 (post‐high‐fat dinner, QD). A 3‐period crossover design with a 72 h washout period; Part 2 (Single‐dose proportionality): 32 participants were equally assigned to four groups, receiving BM2216 SR tablets (5.5, 11, 16.5, or 33 mg) 30 min post‐standard meal, respectively; Part 3 (Multiple‐dose PK comparison): 16 participants were 1:1 randomised into two sequences: (1) BM2216 (post‐dinner, 16.5 mg QD, four consecutive days); (2) 15 mg mirogabalin besylate tablets (fasting 18:00/next‐day 6:00, 7.5 mg/dose, four consecutive days). Crossover was conducted with a 72 h washout period. PK parameters were calculated and compared using non‐compartmental analysis.

Results:

The most common adverse events (AEs) were dizziness (15.6%), increased bile acids (12.5%) and vertigo (12.5%). Dizziness appeared in both the 16.5 and 33 mg dose groups, while vertigo was only seen in the 33 mg group, no serious AEs occurred. Single postprandial doses (5.5–33 mg) exhibited linear PKs: Tmax median 3.00–5.02 h, with dose‐proportional increases in Cmax , AUC 0− t and AUC 0−∞ . Multiple doses (16.5 mg QD, 4 days) had Tmax , ss median 5.996 h, t1/2,ss mean 3.8075 h; The RAC , C max and RAC ,AUC were 0.9965 and 1.0150, indicating no accumulation; high‐fat meal significantly extending T1/2 by 3.5 h, increasing Cmax by 16%, delaying Tmax by 3 h and raising AUC by 30%. Postprandial BM2216 (16.5 mg) and fasting mirogabalin besylate (15 mg) had equivalent mirogabalin AUC; BM2216 showed good sustained‐release properties.

Conclusions:

BM2216 SR was safe and shows linear PK (5.5–3 mg single dose). Due to significant food effect and comparable QD exposure to the reference drug, postprandial QD administration is recommended. These data support further efficacy trials in neuropathic pain patients.

01 Oct 2026·LUMINESCENCE

First Spectrofluorimetric Determination of Mirogabalin in Biological Fluids: A Validated Hantzsch Derivatization Strategy With Full NMR Structural Confirmation

Article

Author: Mostafa, Islam M. ; Sayed, Mostafa ; Mohamed, Abobakr A.

ABSTRACT:

Mirogabalin (MGB) is a new gabapentinoid drug and is designated for peripheral neuropathic pain, involving peripheral neuropathic pain related to diabetes and postherpetic neuralgia. Despite its critical therapeutic importance, reported methods for its determination remain scarce and mainly dependent on LC–MS/MS methods. These published methods demand costly equipment and lengthy sample preparation. Herein, we describe the development and validation of the first spectrofluorimetric report for the sensitive assay of MGB in bulk drug, pharmaceutical tablets, and spiked human urine and plasma. The quantification strategy relies on the Hantzsch condensation reaction between amino group of MGB with acetylacetone and formaldehyde under mildly acidic conditions to produce a strongly fluorescent product. The reaction product was confirmed using 1 H NMR and 13 C NMR analysis. Calibration was linear across 0.1–2.0 μ g/mL in the pure drug standard, with a detection limit of 0.029 μ g/mL and a quantification limit of 0.089 μ g/mL. The linear ranges for spiked human urine and plasma are 0.2–2.0 and 0.1–1.5, respectively. Application to spiked human urine and plasma yielded mean recoveries of 98.28 ± 1.14–98.74 ± 0.91%. Moreover, the introduced was method used for investigating the content uniformity testing of the drug tablets.

News (Medical) associated with Mirogabalin Besilate

31 Jul 2026

·www.biospace.com

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu ® and Datroway ® Fiscal year 2026 guidance for revenue and operating profit revised upward Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the first quarter of fiscal year 2026 as we began execution of our new Five-Year Business Plan,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “Three new U.S. approvals for Enhertu and Datroway were received in a single week in May, underscoring the continued strength of our portfolio where we anticipate delivering more than 20 new indications across five medicines by 2030. These results reinforce the durability of our growth trajectory and support our outlook for fiscal 2026 and beyond.” Q1 FY2026 Results Global revenue increased 21.1% year-over-year to 574.7 billion yen, driven by the company’s global oncology products. Operating profit decreased 12.0% year-over-year to 85.1 billion yen, primarily due to EU Specialty Business restructuring expenses. Global revenue from oncology products was driven by Enhertu ® and Datroway ® , the company's flagship antibody drug conjugates (ADCs). Enhertu revenue, including milestone payments, was 239.8 billion yen, a 48.9% increase. Datroway revenue, including milestone payments, was 23.9 billion yen, a 176.4% increase. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Revenue from the Japan Business was 120.0 billion yen, driven by Lixiana ® and Tarlige ® . ASCA (Asia, South and Central America) Business revenue was 68.7 billion yen, driven by Enhertu. EU Specialty Business revenue was 74.7 billion yen, driven by Lixiana and Nilemdo ® /Nustendi ® . Full fiscal year 2026 guidance has been revised upward from the forecast issued in May 2026. Global revenue is anticipated to increase from 2.28 to 2.34 trillion yen, driven by stronger sales anticipated in the U.S. and favorable foreign exchange rates. Operating profit is anticipated to increase from 315.0 to 320.0 billion yen. Further details on financial performance can be found in the Financial Results Presentation Material . Daiichi Sankyo will host an investor and media conference call and webcast to discuss Q1 FY2026 results on Friday, July 31 at 5:30 pm Japan Standard Time. Q4 FY2025 Results Revision Operating profit has increased from 229.1 billion yen to 258.0 billion yen. Following the announcement of the Q4 FY2025 financial results on May 11, 2026, the Company identified an error in the aggregation process for selling, general and administrative (SG&A) expenses. As a result of the decrease in SG&A expenses, operating profit has been revised upward. Portfolio and Pipeline Highlights Daiichi Sankyo continued to advance its portfolio and pipeline with several milestones across its oncology portfolio, demonstrating momentum towards its goal of launching 20 new indications across five medicines by 2030. Three new breast cancer indications were approved within one week in the U.S. for Enhertu and Datroway in May 2026, including simultaneous approval of two new indications for Enhertu in the neoadjuvant and adjuvant HER2 positive early breast cancer setting based on the DESTINY-Breast11 and DESTINY-Breast05 phase 3 trials, followed by one new indication for Datroway in the first-line metastatic triple negative breast cancer (TNBC) setting for patients not candidates for immunotherapy based on the TROPION-Breast02 phase 3 trial. Datroway received approval in the EU for the same TNBC indication and Enhertu received a positive CHMP opinion for the first-line treatment of HER2 positive metastatic breast cancer based on the DESTINY-Breast09 phase 3 trial in July 2026. A Biologics License Application (BLA) was accepted and granted priority review in the U.S. in April 2026 for ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy, with a Prescription Drug User Fee Act (PDUFA) date of October 10, 2026. Additional regulatory approvals were received in June 2026 for medicines in other major countries/regions. Enhertu received approval in the EU for a HER2 positive metastatic tumor agnostic indication and Vanflyta ® was approved in China in the newly diagnosed setting of FLT3 -ITD positive acute myeloid leukemia (AML). Data from more than 25 abstracts across multiple cancers were presented at the 2026 American Society of Clinical Oncology (#ASCO26) in June 2026. Medicine Indication Q1 FY2026 Update Enhertu Breast Enhertu Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer ( May 2026 ) Enhertu Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer ( July 2026 ) Tumor Agnostic Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors ( June 2026 ) Datroway Breast Datroway Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates ( May 2026 ) Datroway Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy ( July 2026 ) I-DXd Lung Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy ( April 2026 ) Vanflyta AML Vanflyta Approved in China as First and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3 -ITD Positive AML ( June 2026 ) Pipeline Various Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO ( May 2026 ) Corporate Highlights Daiichi Sankyo announced its next Five-Year Business Plan (FY2026 - FY2030) in May 2026 outlining how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognized as a “trusted healthcare innovator transforming the lives of people through our science and technology.” As part of the company’s continued transformation into a global oncology company, Daiichi Sankyo announced in April 2026 that it will transfer in stages all of its shares of Daiichi Sankyo Healthcare Co., Ltd, its over-the-counter drug business in Japan, to Suntory Holdings Limited. The deal is estimated to be completed by June 2029. About Daiichi Sankyo Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit . Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements, including words such as “anticipate,” “estimated,” “favorable,” “goal,” “momentum,” “outlook,” “trajectory,” were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from the outlook of Daiichi Sankyo or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward. Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantees that these compounds will become commercially available in indications under investigation. Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof. The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain. This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion. Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information. Contacts MEDIA CONTACTS: Global: Jennifer Brennan jennifer.brennan@daiichisankyo.com +1 908 900 3183 (mobile) INVESTOR RELATIONS CONTACT: DaiichiSankyoIR_jp@daiichisankyo.com Japan: DS-PR_jp@daiichisankyo.com

Drug ApprovalImmunotherapyPhase 3ASCOFinancial Statement

28 Aug 2024

·www.prnewswire.com

Peripheral Neuropathic Pain Market to Exhibit Growth at a CAGR of 4.1% by 2034 | DelveInsight

The increasing cases of peripheral neuropathic pain, rise in screening for diabetic neuropathic pain among diabetics, increase in the geriatric population, and launch of new approved drugs, among other reasons are likely to fuel the growth of the peripheral neuropathic pain market size during the forecast period (2024–2034). LAS VEGAS, Aug. 28, 2024 /PRNewswire/ --DelveInsight's Peripheral Neuropathic Pain Market Insights report includes a comprehensive understanding of current treatment practices, peripheral neuropathic pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Peripheral Neuropathic Pain Market Report According to DelveInsight's analysis, the market size for peripheral neuropathic pain was found to be ~ USD 12 billion in the 7MM in 2023. The United States accounts for the largest market size of PNP in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. The total cases of peripheral neuropathic pain in the 7MM were approximately 60 million cases in 2023, which are expected to increase during the study period (2020–2034). Leading peripheral neuropathic pain companies such as Lexicon Pharmaceuticals, Merz Therapeutics, Apurano Pharmaceuticals, Vertex Pharmaceuticals, WEX Pharmaceuticals, Scilex Holding Company, and others are developing novel peripheral neuropathic pain drugs that can be available in the peripheral neuropathic pain market in the coming years. The promising peripheral neuropathic pain therapies in the pipeline include LX9211, XEOMIN (incobotulinumtoxinA), Adezunap (AP707), Suzetrigine (VX-548), HALNEURON (Tetrodotoxin or TTX), SEMDEXA (SP-102), and others. Compared to all the emerging therapies, LX9211 and SEMDEXA are expected to become the market leader, having a major influence on the peripheral neuropathic pain market of the 7MM by 2034. In November 2023, Lexicon Pharmaceuticals announced that it has enrolled the first patient in PROGRESS (A Phase IIb, dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension in patients with diabetic peripheral neuropathic pain) studying LX9211. Discover which therapies are expected to grab the major peripheral neuropathic pain market share @ Peripheral Neuropathic Pain Market Report Peripheral Neuropathic Pain Overview Peripheral neuropathies refer to conditions affecting peripheral nerve cells and fibers, arising from a variety of underlying causes. These nerves include the cranial nerves, spinal nerve roots and ganglia, nerve trunks and divisions, and the autonomic nervous system nerves. Peripheral neuropathies can be classified in several ways, such as mononeuropathies, multifocal neuropathies, and polyneuropathies. Mononeuropathy involves damage to a single nerve, while multiple mononeuropathy affects two or more nerves in different locations. Polyneuropathy typically impacts many or most nerves. The diversity of symptoms associated with peripheral neuropathy allows for the identification of distinct clinical phenotypes, which is important for guiding the diagnostic process. Nerve conduction studies are crucial for determining the phenotype and assessing severity. Additional diagnostic tools, such as laboratory tests, genetic testing, cerebrospinal fluid examination, nerve imaging, and nerve biopsy, may be useful in specific clinical situations. Peripheral Neuropathic Pain Epidemiology Segmentation The peripheral neuropathic pain epidemiology section provides insights into the historical and current peripheral neuropathic pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The peripheral neuropathic pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Cases of PNP Type-specific Cases of PNP Treated Cases of PNP Peripheral Neuropathic Pain Treatment Market The treatment of peripheral neuropathic pain depends on the underlying cause and the severity of symptoms. Initial management typically involves conservative measures, including medications such as NSAIDs, acetaminophen, and, in more severe cases, opioids. For radicular symptoms, neuroleptic agents may be used, and systemic steroids are sometimes prescribed for acute low back pain. Nonpharmacological treatments like physical therapy, acupuncture, chiropractic manipulation, and traction are also employed, though their effectiveness is debated. Interventional procedures, such as epidural steroid injections and percutaneous disc decompression, are commonly performed, while surgical options like decompression and spinal fusion are considered for cases that do not respond to other treatments. Pain management for PNP also includes the use of drugs such as NSAIDs, anticonvulsants, and antidepressants, with specific medications like QUTENZA, NUCYNTA ER, and TARLIGE approved for certain patient groups. TARLIGE (mirogabalin besylate) is an oral gabapentinoid developed by Daiichi Sankyo to treat peripheral neuropathic pain (PNP), including diabetic PNP and postherpetic neuralgia. In January 2019, Daiichi Sankyo announced that TARLIGE received approval for marketing in Japan for PNP treatment, offering patients in Japan a new therapeutic option for managing PNP. NUCYNTA ER (tapentadol) is an opioid agonist available as an extended-release film-coated tablet for oral use. It is prescribed for managing neuropathic pain related to diabetic peripheral neuropathy (DPN). In August 2012, the US FDA approved a sNDA for NUCYNTA ER, allowing it to be used as an oral analgesic taken twice daily to manage neuropathic pain in adults with DPN when ongoing, around-the-clock opioid treatment is required for a prolonged duration. The QUTENZA (capsaicin) 8% topical system delivers capsaicin through a localized dermal application. Capsaicin acts as an agonist for the TRPV1 receptor. In July 2020, Grünenthal's US subsidiary, Averitas Pharma, obtained FDA approval for the QUTENZA 8% patch to treat neuropathic pain related to diabetic peripheral neuropathy in the feet of adults. To know more about peripheral neuropathic pain treatment guidelines, visit @ Peripheral Neuropathic Pain Management Peripheral Neuropathic Pain Pipeline Therapies and Key Companies LX9211: Lexicon Pharmaceuticals XEOMIN (IncobotulinumtoxinA): Merz Therapeutics Adezunap (AP707): Apurano Pharmaceuticals Suzetrigine (VX-548): Vertex Pharmaceuticals HALNEURON (Tetrodotoxin or TTX): WEX Pharmaceuticals SEMDEXA (SP-102): Scilex Holding Company Discover more about peripheral neuropathic pain drugs in development @ Peripheral Neuropathic Pain Clinical Trials Peripheral Neuropathic Pain Market Dynamics The peripheral neuropathic pain market dynamics are expected to change in the coming years. Emerging disease-modifying therapies for diabetic neuropathy, CIPN, and LSR are gaining attention due to the growing prevalence of cancer, increased chemotherapy usage, and the large patient pool in need of pain management. The lack of disease-modifying treatment options in the current landscape, which relies solely on symptomatic relief, highlights the market potential for these therapies. Recent developmental activities targeting novel pathways, such as adapter-associated kinase 1 (AAK1) and the Nav1.8 voltage-gated sodium channel, aim to provide opioid-free pain relief, which could lead to a high uptake and the ability to charge a premium price. Furthermore, potential therapies are being investigated for the treatment of peripheral neuropathic pain, and it is safe to predict that the treatment space will significantly impact the peripheral neuropathic pain market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the peripheral neuropathic pain market in the 7MM. However several factors may impede the growth of the peripheral neuropathic pain market. The management of DPN is challenging due to the persistent and severe nature of neuropathic pain, which is frequently ineffectively treated and negatively impacts the quality of life, further complicated by pharmacogenetic and genetic variations in patients; additionally, while improving glycemic control in Type-2 diabetes remains uncertain, the availability of low-cost generics in the treatment landscape may significantly hamper the uptake of emerging therapies, increasing the burden and associated health costs. Moreover, peripheral neuropathic pain treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, peripheral neuropathic pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact peripheral neuropathic pain market growth. Scope of the Peripheral Neuropathic Pain Market Report Therapeutic Assessment: Peripheral Neuropathic Pain current marketed and emerging therapies Peripheral Neuropathic Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Peripheral Neuropathic Pain Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Peripheral Neuropathic Pain Market Access and Reimbursement Download the report to understand which factors are driving peripheral neuropathic pain market trends @ Peripheral Neuropathic Pain Market Trends Table of Contents Related Reports Peripheral Neuropathic Pain Epidemiology Forecast Peripheral Neuropathic Pain Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Peripheral Neuropathic Pain epidemiology trends. Peripheral Neuropathic Pain Pipeline Peripheral Neuropathic Pain Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Peripheral Neuropathic Pain companies, including Haisco Pharmaceutical Group, GlaxoSmithKline, Algiax Pharmaceuticals, Apurano Pharmaceuticals GmbH, Eli Lilly and Company, Shanghai SIMR Biotechnology, Lexicon Pharmaceuticals, among others. Diabetic Neuropathy Market Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, among others. Diabetic Neuropathy Pipeline Diabetic Neuropathy Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical , among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Drug ApprovalPhase 2

18 Dec 2020

·www.biospace.com

Daiichi Sankyo’s Mirogabalin Displays Significant Reduction in Post-SCI Neuropathic Pain

A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with placebo. A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with placebo. The study included 274 patients with central neuropathic pain after spinal cord injury who were randomly assigned to either mirogabalin or placebo. Researchers of the study assessed the change in the average daily pain score, from baseline to week 14. The study found mirogabalin was superior to placebo for improving pain scores over this time period. In addition, the study investigators found no additional safety concerns. Daiichi Sankyo started Phase III trials for mirogabalin in 2015 starting with the REDUCER (An Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of DS-5565 in patients with diabetiC pEripheral neuRopathic pain followed by a 52-week open-label extension) study and the NEUCOURSE (An AsiaN, phasE 3, mUltiCenter, randomized, dOUble-blind, placebo-contRolled 14-week study of DS-5565 in patientS with postherpetic neuralgia followed by a 52-week open-label Extension) study. The recent study findings support results from prior studies conducted by the company in the field of chronic and disease-related pain. Back in 2017, Daiichi Sankyo announced top-line results from a Phase III trial showing mirogabalin was superior to placebo for reducing diabetic peripheral neuropathic pain. Similar to the recent study in central neuropathic pain, investigators in the 2017 study found mirogabalin resulted in significantly greater reductions in the weekly average daily pain score from baseline to week 14. There were also no significant safety concerns in this trial. Pain management has been of particular interest to Daiichi Sankyo, but so far the most promising late-stage studies have been primarily centered in Asia. Just last year, the Japanese pharmaceutical company pulled out of the U.S. pain management market after the company’s CEO decided to shift its focus to oncology. Also, Daiichi Sankyo gave back Movantik , an opioid-induced constipation therapy, to AstraZeneca last year. As it shifts to oncology in the U.S., Daiichi Sankyo announced plans to create an oncology business unit, appointing the company’s president and CEO of the U.S. Ken Keller to the role of U.S. business chief once it opens April 2021. A statement made by the company says the new business unit will align “The U.S. and European oncology businesses, global oncology functions of marketing, market access and pricing, medical affairs as well as alliance management under one team singularly devoted to people with cancer.” This transition from a small-molecule metabolic and cardiovascular pharmaceutical organization to an oncology biologics maker is part of Daiichi Sankyo’s 2025 business plan. So far, the shift to oncology has landed the company one major approval, with other imminent approvals likely on their way. In January, the company and AstraZeneca’s HER2-targeting therapy Enhertu was approved as a third-line therapy for hard-to-treat metastatic breast cancer therapy. The approval triggered a milestone payment of $125 million from AstraZeneca to Daiichi Sankyo. Also, Enhertu was recently granted priority review from the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive, metastatic gastric or gastroesophageal junction cancer. The FDA will make the final decision on whether to approve this drug in early 2021. Featured Jobs on BioSpace

Phase 3Drug ApprovalExecutive ChangeClinical ResultPriority Review

100 Deals associated with Mirogabalin Besilate

External Link

KEGG	Wiki	ATC	Drug Bank
D10790 D11203	Mirogabalin Besilate	N	DB11825

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetic peripheral neuropathic pain	China	Daiichi Sankyo Co., Ltd.	28 Jun 2024
Neuralgia	Japan	Daiichi Sankyo Co., Ltd.	08 Jan 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuralgia, Postherpetic	Phase 3	Japan	Daiichi Sankyo Co., Ltd.	01 Dec 2015
Fibromyalgia	Phase 3	United States	Daiichi Sankyo Co., Ltd.	27 Oct 2014
Fibromyalgia	Phase 3	Canada	Daiichi Sankyo Co., Ltd.	27 Oct 2014
Fibromyalgia	Phase 3	Czechia	Daiichi Sankyo Co., Ltd.	27 Oct 2014
Fibromyalgia	Phase 3	Denmark	Daiichi Sankyo Co., Ltd.	27 Oct 2014
Fibromyalgia	Phase 3	Finland	Daiichi Sankyo Co., Ltd.	27 Oct 2014
Fibromyalgia	Phase 3	France	Daiichi Sankyo Co., Ltd.	27 Oct 2014
Fibromyalgia	Phase 3	Germany	Daiichi Sankyo Co., Ltd.	27 Oct 2014
Fibromyalgia	Phase 3	Netherlands	Daiichi Sankyo Co., Ltd.	27 Oct 2014
Fibromyalgia	Phase 3	Norway	Daiichi Sankyo Co., Ltd.	27 Oct 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT07157852 (Pubmed \| BMJ Open)	Phase 3	Fibromyalgia	674	Mirogabalin	hsmwtlyrah(jhctrpuqwq) = trpewadkfa mwmdtqgrwn (gymirsnttn ) View more	Positive	01 Aug 2026
				Pregabalin	hsmwtlyrah(jhctrpuqwq) = zmjbmpmvkt mwmdtqgrwn (gymirsnttn ) View more
SmiliNg (ASCO2026)	Phase 2	-	30	Mirogabalin	yoltvwjdvi(usfhimxjxe) = AST/ALT increased, and pulmonary infection, each occurring in one patient; none were related to mirogabalin treatment. ngrdlwuuoq (camafsdwsj ) View more	Positive	29 May 2026
NCT03901352 (CTgov)	Phase 3	Neuralgia	300	Mirogabalin (Mirogabalin)	sqkxjdpjlw(xmphwiajfs) = vvgnzezoax uvvwjagvwm (aajnnlgspx, 0.132) View more	-	23 Sep 2024
				Placebo (Placebo)	sqkxjdpjlw(xmphwiajfs) = rhskdufdak uvvwjagvwm (aajnnlgspx, 0.132) View more
NCT04094662 (Pubmed)	-	Diabetic peripheral neuropathic pain	393	美洛加巴林	eshtkipcoz(eyziyirwwm) = ggedumubdq tqcrpzolsm (nkhwjltcyo ) View more	Positive	01 Aug 2024
				安慰剂	eshtkipcoz(eyziyirwwm) = opujnjmoms tqcrpzolsm (nkhwjltcyo ) View more
JPRN-jRCTs031210101 (MiroCIP study, Pubmed \| BMC Cancer)	Not Applicable	Peripheral Nervous System Diseases	58	Mirogabalin 5-15 mg twice daily	crvqdapinu(ltjjmtzuud) = xcjznnzjoq thdquxisnb (jyjgwlwdhf ) View more	Positive	11 Nov 2023
NCT03901352 (Pubmed)	Phase 3	Neuralgia	-	Mirogabalin	zrkccckgxa(ushdquofdu): odds ratio = 1.91 (95% CI, 1.11 - 3.27)	Positive	14 Dec 2022
				Placebo
NCT02318719 \| NCT02318706 (Pubmed \| Clin Ther)	Phase 3	Neuralgia	1,587	Placebo	nsjaboehwk(apybzntwgh) = qhvwxncvfq xqnhhqjrfv (uilnbkxeuw ) View more	-	28 May 2021
				Mirogabalin 15-mg once daily	nsjaboehwk(apybzntwgh) = yfbkwozjht xqnhhqjrfv (uilnbkxeuw ) View more
NCT01496365 (CTgov)	Phase 2	Neuralgia \| Diabetic peripheral neuropathy	452	placebo (Placebo)	nwuibokpub(lahsaztodx) = lbcvflxgfm iichmxdxam (uhoeboyewj, 2.18) View more	-	05 Jan 2021
				Pregabalin (Pregabalin 150 mg BID)	nwuibokpub(lahsaztodx) = yrnbgotpkr iichmxdxam (uhoeboyewj, 2.27) View more
NCT02146430 (CTgov)	Phase 3	Pain \| Fibromyalgia	1,293	Placebo capsule (Placebo)	cswdkbvbyn(sgpxupnriq) = flxmnxgjhu udbpipxjdt (zmrukvylmk, 0.132) View more	-	09 Nov 2020
				Placebo tablet+Pregabalin (Pregabalin)	ffjaabmrtx(sucripwthf) = reliqqsyig akxtabkumh (nkntfomgcm, pofoctgjxx - kkclkouatt) View more
NCT02187159 (CTgov)	Phase 3	Pain \| Fibromyalgia	1,270	Placebo capsule	snlqbjutkt(zkbnqypkwa) = qdrdwnrxat qpkhneklrt (jmcqihruwx, 0.130) View more	-	09 Nov 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis